ENHERTU (Daiichi Sankyo, Inc.)
(https://enhertu.com) 📸 Data Snapshot: June 20, 2026
Identity & Authority — The Lens
Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.
Identity & Authority
Expert verifiability & Schema depth.
15
Impact Weight: 15 / 100
100% Reputation
There are no authority gaps; the site provides comprehensive schema_json identifying Daiichi Sankyo as the creator and linking to high-authority nodes like Wikipedia for the drug and manufacturer. The inclusion of ‘Boxed WARNINGS’ and detailed pregnancy/breastfeeding warnings demonstrates a high level of regulatory authority and transparency. The technical implementation is professional with no broken hierarchies or missing structured data.
The performance claims are remarkably grounded, with the site explicitly stating that ENHERTU is ‘still being studied to confirm these results’ for certain indications. Marketing tone is present in the ‘Hopeful woman at beach’ imagery, but it is immediately balanced by the legal disclaimer ‘Not actual patients.’ There are no bold claims of ‘curing’ cancer, only clinical response measurements.
Identity & Authority is read from the structured data first: whether the site declares who it is in machine-readable schema, with verifiable identity links. Below is the schema captured per page, then the external proof links that support (or fail to support) that identity.
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps
Homepage schema
{
"@context": "https://schema.org/",
"@type": "MedicalWebPage",
"url": "https://www.enhertu.com/",
"audience": "https://health-lifesci.schema.org/Patient",
"creator": {
"@type": "Organization",
"name": "Daiichi Sankyo, Inc",
"url": "https://daiichisankyo.us",
"logo": "https://daiichisankyo.us/home",
"sameAs": "https://en.wikipedia.org/wiki/Daiichi_Sankyo"
},
"mainEntity": {
"@type": "Drug",
"name": "ENHERTU",
"sameAs": "https://en.wikipedia.org/wiki/Trastuzumab_deruxtecan",
"image": "https://www.enhertu.com/-/media/enhertu_patient/images/gateway/enhertu-logo.ashx",
"legalStatus": "FDA Approved",
"activeIngredient": "fam-trastuzumab deruxtecan-nxki",
"nonProprietaryName": "fam-trastuzumab deruxtecan-nxki",
"isProprietary": "True",
"isAvailableGenerically": "False",
"relevantSpecialty": "https://health-lifesci.schema.org/Oncologic",
"manufacturer": {
"@type": "Organization",
"name": "Daiichi Sankyo, Inc",
"url": "https://daiichisankyo.us",
"logo": "https://daiichisankyo.us/home",
"sameAs": "https://en.wikipedia.org/wiki/Daiichi_Sankyo"
},
"description": "Learn more about ENHERTU® (famtrastuzumab deruxtecan-nxki) for several types of cancer. See Full Safety and Boxed WARNINGS for more information.",
"drugUnit": "100 mg lyophilized powder in a single-dose vial",
"dosageForm": "Injection for Intravenous Use",
"labelDetails": "https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true",
"administrationRoute": "IV infusion",
"prescriptionStatus": "https://health-lifesci.schema.org/PrescriptionOnly",
"prescribingInfo": "https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true",
"foodWarning": "",
"alcoholWarning": "",
"pregnancyWarning": "Harm to your unborn baby. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with ENHERTU. If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with ENHERTU. Females who are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for at least 7 months after the last dose. Males who have female partners that are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for at least 4 months after the last dose.",
"breastfeedingWarning": "Before you receive ENHERTU, tell your healthcare provider about all of your medical conditions, including if you are breastfeeding or plan to breastfeed. It is not known if ENHERTU passes into your breast milk. Do not breastfeed during treatment with ENHERTU and for 7 months after the last dose.",
"mechanismOfAction": "As a targeted treatment called an antibody-drug conjugate (ADC), ENHERTU is designed to work differently than traditional chemotherapies. 1. ENHERTU is made up of an antibody with the chemotherapy attached 2. The antibody part of ENHERTU targets and attaches to HER2 on the cancer cell 3. ENHERTU enters the cancer cell and the chemotherapy is released 4. The chemotherapy part of ENHERTU helps destroy the cancer cell as well as other cells nearby Although ENHERTU is designed to target HER2 on cancer cells, it may affect some healthy cells. ENHERTU may not work for everyone.",
"interactingDrug": ""
},
"about": [
{
"@type": "MedicalCondition",
"name": "HER2+ Metastatic Breast Cancer",
"alternateName": "HER2+ mBC",
"associatedAnatomy": {
"@type": "AnatomicalStructure",
"name": "Breast"
},
"relevantSpecialty": "https://health-lifesci.schema.org/Oncologic",
"possibleTreatment": {
"@type": "MedicalTherapy",
"drug": {
"@type": "Drug",
"name": "ENHERTU"
}
}
},
{
"@type": "MedicalCondition",
"name": "HER2+ Advanced Stomach Cancer",
"alternateName": "HER2+ aGC",
"associatedAnatomy": {
"@type": "AnatomicalStructure",
"name": "Stomach"
},
"relevantSpecialty": "https://health-lifesci.schema.org/Oncologic",
"possibleTreatment": {
"@type": "MedicalTherapy",
"drug": {
"@type": "Drug",
"name": "ENHERTU"
}
}
},
{
"@type": "MedicalCondition",
"name": "HER2 Mutant Metastatic Lung Cancer",
"alternateName": "HER2 Mutant NSCLC",
"associatedAnatomy": {
"@type": "AnatomicalStructure",
"name": "Lung"
},
"relevantSpecialty": "https://health-lifesci.schema.org/Oncologic",
"possibleTreatment": {
"@type": "MedicalTherapy",
"drug": {
"@type": "Drug",
"name": "ENHERTU"
}
}
},
{
"@type": "MedicalCondition",
"name": "HER2-low Metastatic Breast Cancer",
"alternateName": "HER2-low mBC",
"associatedAnatomy": {
"@type": "AnatomicalStructure",
"name": "Breast"
},
"relevantSpecialty": "https://health-lifesci.schema.org/Oncologic",
"possibleTreatment": {
"@type": "MedicalTherapy",
"drug": {
"@type": "Drug",
"name": "ENHERTU"
}
}
}
]
}
/en/
{
"@context": "https://schema.org/",
"@type": "MedicalWebPage",
"url": "https://www.enhertu.com/",
"audience": "https://health-lifesci.schema.org/Patient",
"creator": {
"@type": "Organization",
"name": "Daiichi Sankyo, Inc",
"url": "https://daiichisankyo.us",
"logo": "https://daiichisankyo.us/home",
"sameAs": "https://en.wikipedia.org/wiki/Daiichi_Sankyo"
},
"mainEntity": {
"@type": "Drug",
"name": "ENHERTU",
"sameAs": "https://en.wikipedia.org/wiki/Trastuzumab_deruxtecan",
"image": "https://www.enhertu.com/-/media/enhertu_patient/images/gateway/enhertu-logo.ashx",
"legalStatus": "FDA Approved",
"activeIngredient": "fam-trastuzumab deruxtecan-nxki",
"nonProprietaryName": "fam-trastuzumab deruxtecan-nxki",
"isProprietary": "True",
"isAvailableGenerically": "False",
"relevantSpecialty": "https://health-lifesci.schema.org/Oncologic",
"manufacturer": {
"@type": "Organization",
"name": "Daiichi Sankyo, Inc",
"url": "https://daiichisankyo.us",
"logo": "https://daiichisankyo.us/home",
"sameAs": "https://en.wikipedia.org/wiki/Daiichi_Sankyo"
},
"description": "Learn more about ENHERTU® (famtrastuzumab deruxtecan-nxki) for several types of cancer. See Full Safety and Boxed WARNINGS for more information.",
"drugUnit": "100 mg lyophilized powder in a single-dose vial",
"dosageForm": "Injection for Intravenous Use",
"labelDetails": "https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true",
"administrationRoute": "IV infusion",
"prescriptionStatus": "https://health-lifesci.schema.org/PrescriptionOnly",
"prescribingInfo": "https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true",
"foodWarning": "",
"alcoholWarning": "",
"pregnancyWarning": "Harm to your unborn baby. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with ENHERTU. If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with ENHERTU. Females who are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for at least 7 months after the last dose. Males who have female partners that are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for at least 4 months after the last dose.",
"breastfeedingWarning": "Before you receive ENHERTU, tell your healthcare provider about all of your medical conditions, including if you are breastfeeding or plan to breastfeed. It is not known if ENHERTU passes into your breast milk. Do not breastfeed during treatment with ENHERTU and for 7 months after the last dose.",
"mechanismOfAction": "As a targeted treatment called an antibody-drug conjugate (ADC), ENHERTU is designed to work differently than traditional chemotherapies. 1. ENHERTU is made up of an antibody with the chemotherapy attached 2. The antibody part of ENHERTU targets and attaches to HER2 on the cancer cell 3. ENHERTU enters the cancer cell and the chemotherapy is released 4. The chemotherapy part of ENHERTU helps destroy the cancer cell as well as other cells nearby Although ENHERTU is designed to target HER2 on cancer cells, it may affect some healthy cells. ENHERTU may not work for everyone.",
"interactingDrug": ""
},
"about": [
{
"@type": "MedicalCondition",
"name": "HER2+ Metastatic Breast Cancer",
"alternateName": "HER2+ mBC",
"associatedAnatomy": {
"@type": "AnatomicalStructure",
"name": "Breast"
},
"relevantSpecialty": "https://health-lifesci.schema.org/Oncologic",
"possibleTreatment": {
"@type": "MedicalTherapy",
"drug": {
"@type": "Drug",
"name": "ENHERTU"
}
}
},
{
"@type": "MedicalCondition",
"name": "HER2+ Advanced Stomach Cancer",
"alternateName": "HER2+ aGC",
"associatedAnatomy": {
"@type": "AnatomicalStructure",
"name": "Stomach"
},
"relevantSpecialty": "https://health-lifesci.schema.org/Oncologic",
"possibleTreatment": {
"@type": "MedicalTherapy",
"drug": {
"@type": "Drug",
"name": "ENHERTU"
}
}
},
{
"@type": "MedicalCondition",
"name": "HER2 Mutant Metastatic Lung Cancer",
"alternateName": "HER2 Mutant NSCLC",
"associatedAnatomy": {
"@type": "AnatomicalStructure",
"name": "Lung"
},
"relevantSpecialty": "https://health-lifesci.schema.org/Oncologic",
"possibleTreatment": {
"@type": "MedicalTherapy",
"drug": {
"@type": "Drug",
"name": "ENHERTU"
}
}
},
{
"@type": "MedicalCondition",
"name": "HER2-low Metastatic Breast Cancer",
"alternateName": "HER2-low mBC",
"associatedAnatomy": {
"@type": "AnatomicalStructure",
"name": "Breast"
},
"relevantSpecialty": "https://health-lifesci.schema.org/Oncologic",
"possibleTreatment": {
"@type": "MedicalTherapy",
"drug": {
"@type": "Drug",
"name": "ENHERTU"
}
}
}
]
}
/en/breast/ — no schema detected (entity gap)
/en/her2-low-breast/
{
"@context": "https://schema.org/",
"@type": "MedicalWebPage",
"url": "https://www.enhertu.com/en/her2-low-breast",
"description": "Learn about ENHERTU® (fam-trastuzumab deruxtecan-nxki), including clinical trial results and safety data. See the full Important Safety Information, Prescribing Information, including Boxed WARNINGS, and Medication Guide for more information.",
"sameAs": "https://en.wikipedia.org/wiki/Trastuzumab_deruxtecan",
"medicalAudience": "https://health-lifesci.schema.org/Patient",
"creator": {
"@type": "Organization",
"name": "Daiichi Sankyo, Inc",
"url": "https://daiichisankyo.us/home",
"logo": "https://enhertu.com/-/media/enhertu_patient/images/footer/daiichi-sankyo-astra-zeneca-logo.ashx",
"sameAs": "https://en.wikipedia.org/wiki/Daiichi_Sankyo"
},
"specialty": [
"https://health-lifesci.schema.org/Oncologic",
"https://schema.org/Oncologic"
],
"mainEntity": {
"@id": "https://enhertu.com/en/her2-low-breast#Drug",
"@type": "Drug",
"name": "ENHERTU",
"brand": {
"@type": "Brand",
"name": "ENHERTU",
"logo": "https://enhertu.com/-/media/enhertu_patient/images/header/enhertu-logo.ashx",
"description": "Find valuable information about ENHERTU® (fam-trastuzumab deruztecan-nxki), including clinical trial results, safety information, downloadable resources, and more. See Full Safety, Boxed WARNINGS, & Medication Guide for more information.",
"sameAs": "https://en.wikipedia.org/wiki/Trastuzumab_deruxtecan"
},
"isProprietary": "True",
"isAvailableGenerically": "False",
"nonProprietaryName": "fam-trastuzumab deruxtecan-nxki",
"activeIngredient": "fam-trastuzumab deruxtecan-nxki",
"administrationRoute": "IV infusion",
"alcoholWarning": "N/A",
"breastfeedingWarning": "Before you receive ENHERTU, tell your healthcare provider about all of your medical conditions, including if you:\n o have lung or breathing problems\n o have signs or symptoms of an infection\n o have or have had any heart problems\n o are breastfeeding or plan to breastfeed. It is not known if ENHERTU passes into your breast milk. Do not breastfeed during treatment with ENHERTU and for 7 months after the last dose.",
"dosageForm": "Injection for intravenous use",
"drugUnit": "100 mg lyophilized powder in a single-dose vial",
"foodWarning": "N/A",
"labelDetails": "https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true",
"mechanismOfAction": "As a targeted treatment called an antibody-drug conjugate (ADC), ENHERTU is designed to work differently than traditional chemotherapies. \n\n1. ENHERTU is made up of an antibody with the chemotherapy attached \n2. The antibody part of ENHERTU targets and attaches to HER2 on the cancer cell \n3. ENHERTU enters the cancer cell and the chemotherapy is released \n4. The chemotherapy part of ENHERTU helps destroy the cancer cell as well as other cells nearby \n\nAlthough ENHERTU is designed to target HER2 on cancer cells, it may affect some healthy cells. ENHERTU may not work for everyone.",
"prescribingInfo": "https://daiichisankyo.us/prescribing-information-portlet/getPIContent?productName=Enhertu&inline=true",
"prescriptionStatus": "https://health-lifesci.schema.org/PrescriptionOnly",
"manufacturer": {
"@type": "Organization",
"name": "Daiichi Sankyo, Inc",
"url": "https://www.daiichisankyo.us",
"logo": "https://daiichisankyo.us/documents/d/dsi/logo",
"sameAs": "https://en.wikipedia.org/wiki/Daiichi_Sankyo"
},
"pregnancyWarning": "• Harm to your unborn baby. Tell your healthcare provider right away if you become pregnant or think you might be pregnant during treatment with ENHERTU. \n o If you are able to become pregnant, your healthcare provider should do a pregnancy test before you start treatment with ENHERTU. \n o Females who are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for 7 months after the last dose. \n o Males who have female partners that are able to become pregnant should use effective birth control (contraception) during treatment with ENHERTU and for 4 months after the last dose.",
"interactingDrug": "N/A",
"doseSchedule": {
"@type": "DoseSchedule",
"doseUnit": "mg/kg",
"doseValue": "5.4",
"frequency": "Once every 3 weeks",
"targetPopulation": "Adults"
}
},
"about": {
"@type": "MedicalCondition",
"name": "HER2-low and HR+, HER2-ultralow Metastatic Breast Cancer",
"alternateName": "HER2-low and HR+, HER2-ultralow mBC",
"associatedAnatomy": {
"@type": "AnatomicalStructure",
"name": "Breast"
},
"possibleTreatment": {
"@id": "https://enhertu.com/en/her2-low-breast#Drug"
}
}
}
🛡️ Trust Signals — external proof links that back the declared identity
0Review mentions (all pages)
0External proof links (all pages)
| Page | Reviews | Proof links |
|---|---|---|
| / (home) | 0 | 0 |
| /en/ | 0 | 0 |
| /en/breast/ | 0 | 0 |
| /en/her2-low-breast/ | 0 | 0 |
Explore the other reputation pillars for ENHERTU (Daiichi Sankyo, Inc.)
Analysis Disclosure & Source Attribution
This page presents a snapshot of public data from ENHERTU (Daiichi Sankyo, Inc.), captured on June 20, 2026, to show how machine logic reads Identity & Authority signals into an AI reputation evaluation.
Purpose: This data is presented under “Fair Use” for the purpose of independent signal analysis, allowing readers to see the raw signals behind the reputation score.
Notice to ENHERTU (Daiichi Sankyo, Inc.): This analysis is part of a non-adversarial audit conducted by 1 Euro SEO. The results are intended as professional feedback to help improve any website’s machine-readability and authority signals. The evaluation is free, and any company can request a fresh audit at any time.
Any company can use the insights for free and improve its voice. When a company has updated its content, it can always submit a new audit request, which will be reflected in a new current score.
To all users: You are encouraged to visit the live site at https://enhertu.com to view the most current version of its content and see directly what this company is about and what it offers.